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Background: The serious consequences of diabetes mellitus, and the subsequent economic burden, call for urgent
preventative action in developing countries. This study explores the clinical and economic outcomes of strategies
that could potentially prevent diabetes based on Chinese circumstances. It aims to provide indicators for the
long-term allocation of healthcare resources for authorities in developing countries.
Methods: A representative sample of Chinese adults was used to create a simulated population of 20,000 people aged
25 years and above. The hybrid decision tree Markov model was developed to compare the long-term clinical and
economic outcomes of four simulated diabetes prevention strategies with a control group, where no prevention applied.
These preventive strategies were the following: (i) one-off screening for undiagnosed diabetes and impaired glucose
tolerance (IGT), with lifestyle interventions on diet, (ii) on exercise, (iii) on diet combined exercise (duo-intervention)
respectively in those with IGT, and (iv) one-off screening alone. Independent age-specific models were simulated based
on diverse incidences of diabetes, mortalities and health utilities. The reported outcomes were the following: the
remaining survival years, the quality-adjusted life years (QALYs) per diabetes or IGT subjects, societal costs per simulated
subject and the comparisons between preventions and control over 40 years. Sensitivity analyses were performed based
on variations of all assumptions, in addition to the performance and the compliance of screening.
Results: Compared with the control group, all simulated screening programmes prolonged life expectancy at the
initiation ages of 25 and 40 years, postponed the onset of diabetes and increased QALYs at every initiation age. Along
with an assumption of six years intervention, prevention programmes were associated with cost-saving compared with
the control group, especially in the population aged 25 years. The savings were at least US$2017 per subject, but no
statistically significant difference was observed among the intervention strategies within each age groups. The cost
savings were reduced when screening was affected by poor performance and noncompliance.
Conclusions: Developing countries have few effective strategies to manage the prevention of diabetes. One-off
screening for undiagnosed diabetes and IGT, with appropriate lifestyle interventions for those with IGT are cost saving in
China, especially in young adults.Background
Diabetes mellitus is expected to become one of the most
serious health problems in the world within the next
25 years [1]. The number of patients with diabetes has
increased dramatically in developing countries [2], espe-
cially in China. Currently, China has the largest diabetes* Correspondence: junma@tijmu.edu.cn
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reproduction in any medium, provided the orpopulation among developing nations with approximately
92.4 million adults aged 20 years or older, of which 60.7%
are undiagnosed [3]. In China, the direct medical costs of
diabetes and related complications is estimated to have
been US$26.0 billion in 2007, which represented 81% of
total medical care costs [4]. These costs are expected to
increase to $47.2 billion by 2030. In addition, direct health
expenditure on diabetes accounted for 18.2% of total gov-
ernment annual health expenditure in 2007, which was
much higher than that of developed countries [5], such as
Spain with 7.4% [6], USA with 11.9% [7] and GermanyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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betes is an important public health challenge for China.
However, at present, there is no systematic prevention
strategy for diabetes, despite the fact that it is considered a
fundamental component of the nation’s health policies [9].
Screening for undiagnosed diabetes and pre-diabetes
could provide early diagnosis and could allow for medical
treatment to start, thus slowing down the progress of the
disease. Another effective approach is lifestyle interven-
tion, which, over the last century, has been shown to re-
sult in a dramatic decrease in the incidence of diabetes in
both developed and developing countries [10-17]. How-
ever, it is not certain whether such strategies should be
brought together and implemented in developing coun-
tries with their limited health resources, since no reported
evaluations exist in countries like China to show whether
these prevention strategies are economically viable.
At present, there have been no clinical trials evaluating
the economic effects of screening for pre-diabetes at vari-
ous ages, with or without interventions. Most recommen-
dations for non-pharmacological preventions of diabetes
have been based on mathematical models [13,18-29]. In
most of these models, favourable results have been gener-
ated by simulating screening or intervention strategies
alone, and these strategies have been carried out in high-
income areas, rather than in developing countries. There
has been one study that compared screening followed by
interventions with no screening [26]. Unfortunately, this
study did not consider an appropriate initiation age for
the prevention strategies.
To address the above issues, we collected data from
high-quality studies that involved the detection and pre-
vention of diabetes in China. Based on these studies, a
hybrid decision tree Markov model was performed to es-
timate the clinical and economic outcomes of screening
for undiagnosed diabetes and impaired glucose tolerance
(IGT), followed by the implementation of lifestyle inter-
vention in those with IGT. By comparing these results
with no screening, the dominant strategies and targeted
populations were selected. It is hoped that these findings
will provide a model for authorities of developing coun-
tries to optimise the allocation of health resources.
Methods
Selected model inputs and assumptions are shown in
Tables 1 and 2. Estimated parameters, prevention and
treatment costs, and health-related quality of life weight
(also called utility score or utility) were obtained from
published data. The screening unit cost was derived from
Publicity Medicine Prices of Hunan, China.
Study design
Because there are no primary prevention policies being
generally implemented in developing countries, we builta hybrid model, which was constructed by a decision
tree and Markov models, to simulate potential screening
and lifestyle intervention strategies for the prevention of
diabetes (Figure 1). The decision tree included five main
arms representing five scenarios. The first three scenar-
ios involved screening for undiagnosed diabetes and IGT
followed by one of the three active lifestyle interventions
(diet, exercise or duo-intervention), which were applied
to the IGT subjects. The fourth scenario involved
screening for undiagnosed diabetes and IGT, but without
the formal lifestyle interventions. The fifth scenario in-
volved the control group with no screening or interven-
tion. The simulated individuals were subjected to one of
the five different strategies in sequence.
The decision tree used positive screening rates and the
prevalence of diabetes and IGT in the reference population
to determine how many individuals started in each state of
the Markov models. Each Markov model consisted of eight
main health states: IGT, normal glucose tolerance, onset of
diabetes, four diabetes complication states and death.
Among these, the IGT states contained subjects who had a
2-h plasma glucose (PG) concentration between 6.7 and
11.1 mmol/L. These states were tunnel states that included
six temporary ones representing 6 years of lifestyle inter-
vention. The simulated IGT subjects underwent the tunnel
states until they reached either normal glucose tolerance,
onset of diabetes or death. The normal glucose tolerance
state applied to subjects who had a 2-h PG <6.7 mmol/L.
The onset of diabetes state applied to subjects who had a
2-h PG >11.1 mmol/L [30]. There were four diabetes com-
plication states: cardiovascular disease (CVD), including
myocardial infarction or stroke [35], retinopathy, including
proliferative retinopathy, photocoagulation or blindness,
nephropathy, including end-stage renal disease or renal re-
placement, and overt neuropathy, including abnormal
touch sensation, ulceration or extremity amputation [36].
The last state, death, contained subjects who died from
natural causes or from diabetes.
The Markov models ran for a time horizon of 40 years,
and each of the model cycles represented 1 year. Separ-
ate simulations with different incidence rates of diabetes,
mortality rates and health utilities were performed for
the diabetes prevention programmes or for the control
starting at 25, 40 and 60 years, respectively.
The hybrid model parameters were estimated by using
Markov chain Monte Carlo simulation methods [28],
and results were derived from a sample of 20,000 simu-
lations. The main outcomes analysed in the model were
the remaining survival years and the health effectiveness
QALYs per subject with diabetes or IGT, the life-years
gained before the onset of diabetes or before the onset
of any kind of complication per subject with IGT and
the cost per subject for prevention strategies or control
at the different initiation ages.
Table 1 Baseline values of input parameters used in models (Epidemiology parameters and costs (US$))








Negative rate of 2-h PG¢ 0.96 0.96 0.96 0.96 − [30]
Positive rate of OGTT£ 0.305 0.305 0.305 0.305 − [30]
Proportion of Diagnosed IGT¤ 0.478 0.478 0.478 0.478 − [30]
Normal PG to IGT§ 0.0128 0.0128 0.0128 0.0128 0.0128 [30,31]
IGT to onset of diabetes¶
Initiation age of 25 0.0290 0.0273 0.0275 0.0400 0.0644 [12,32,33]
Initiation age of 40 0.0754 0.0710 0.0716 0.104 0.1670 [12,32]
Initiation age of 60 0.2320 0.2184 0.2200 0.3600 0.5778 [12,32,33]
IGT to normal PGß 0.116 0.116 0.116 0.116 0.116 [34]
Onset of diabetes to CVDð1 0.062 0.062 0.062 0.0675 0.0675 [35,36]
Onset of diabetes to Nephropathyð2 0.001 0.001 0.001 0.001 0.001 [35,36]
Onset of diabetes to Neuropathyð3 0.0043 0.0043 0.0043 0.005 0.005 [35,36]
Onset of diabetes to Retinopathyð4 0.0046 0.0046 0.0046 0.0081 0.0081 [35,36]
CVD to death&1 0.0058 0.0058 0.0058 0.0087 0.0087 [35,36]
Nephropathy to death&2 0.0008 0.0008 0.0008 0.0003 0.0003 [35,36]
Costs (US$)a
Cost for screening 3 3 3 3 − [37]
Diet or exercise intervention 362 362 − − − [38]
Duo-intervention − − 371 − − [38]
Onset of diabetes 897 897 897 897 897 [5]
CVD treatment 2078 2078 2078 2078 2078 [5]
Nephropathy treatment 1089 1089 1089 1089 1089 [5]
Neuropathy treatment 1324 1324 1324 1324 1324 [5]
Retinopathy treatment 888 888 888 888 888 [5]
The hybrid tree combined a decision tree and Markov models. The decision tree consisted of five main arms representing five scenarios. The first three scenarios
involved screening for undiagnosed diabetes and IGT followed by any of the three active lifestyle interventions (diet, exercise, and duo-intervention), which were
applied to the IGT subjects. The fourth scenario involved screening for undiagnosed diabetes and IGT, but without formal interventions (physicians dispensed
information brochures only), and the fifth scenario involved control group with no screening or intervention. ‘OGTT’ means oral glucose tolerance test. ‘IGT’
means impaired glucose tolerance. ‘PG’ means plasma glucose. ‘CVD’ means cardiovascular disease. Costs(US$)a involved following costs: unit costs of one-off
screening (test of 2-hour PG after breakfast, a confirmatory OGTT), and were derived from the national standard prices of medicines in China; costs of lifestyle
interventions (diet or exercise intervention, and duo-intervention) were the average annual costs and obtained from a domestic community-based trial in China
[38]; treatment costs of diabetes-related disorders were derived from a study of treatment costs for diabetes in China [5]. The transition parameters were
numbered corresponding to the transition paths in Figure 1. (#The complement probabilities of one branch. *The life-table information which was used to model
competing causes of death. @The proportion of individuals with normal PG. ¢, £, ¤ Transition parameters which determined whether a subject would receive
interventions. §, ¶, ð, &: Transition parameters used in the Markov models, among these, ð1 to ð4 determined four transitions from onset of diabetes state to
different complications states (cardiovascular disease, retinopathy, nephropathy and overt neuropathy) respectively; &1 and &2 determined two transitions from
CVD or nephropathy state to death state. We did not consider the neuropathy-specific and retinopathy-specific mortalities, since these complications are
not fatal).
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The subjects with 2-h PG ≥6.67 mmol/L after breakfast
were given an oral glucose tolerance test (OGTT) [30].
The IGT subjects diagnosed from screening received dif-
ferent types of lifestyle interventions [12]. The diet group
were encouraged to consume more vegetables and to con-
trol their intake of alcohol and simple sugars. The exercise
group were taught and encouraged to increase their leis-
ure physical activity, and the duo-intervention groups
were given information regarding both diet and exercise.Participants in these three groups received individual
counselling from physicians or the counselling sessions.
These interventions continued for six years with an aver-
age of nine sessions a year. The group that had screening
alone only received information brochures with general
instructions on diet or exercise from clinic physicians [12].
Epidemiological variables
Data from a population-based cross-sectional study of
110,660 residents aged 25–74 years in China were used to
Table 2 Utilities assigned to various health states of






age of 60 References
Normal PG 1 1 1 −
IGT 0.95 0.95 0.95 [19]
Onset of diabetes 0.805 0.800 0.794 [39,40]
CVD 0.679 0.674 0.584 [39,40]
Retinopathy 0.705 0.700 0.610 [39,40]
Nephropathy 0.646 0.641 0.551 [39,40]
Neuropthy 0.667 0.662 0.572 [39,40]
Death 0 0 0 −
The unadjusted median utilities for diabetes-related disorders
represented the median age and median social demography of
individuals having diabetes, thus, these values were assigned to
individuals aged 40 years [39,40]. By using the coefficient of age and
three disorder conditions to adjust the baseline estimate of initiation age
at 40, the utilities of 60-year-old subjects with a complication were
determined. For example, the utility of subjects with diabetes having
CVD at initiation age of 60 was 0.584. It was derived from the median
utility for diabetes with CVD (0.674) subtracting 0.006 ((60–40)*(−0.0003))
and 0.084 (coefficient of three conditions included diabetes with CVD).
For subjects aged 25 years, the calculation of utilities only considered the
impact of age (coefficient of age was used to adjust the baseline
estimates of aged 40 years) [40].
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ing methods and screening positive rates [30]. The annual
incidence of IGT was deduced from the prevalence rate of
IGT [30] and the average time before diagnosis of diabetes
[31]. The annual transition rate from the IGT state to nor-
mal glucose tolerance was calculated using a 3-year cumu-
lative incidence of a spontaneous return to normal
glucose tolerance [34]. Based on data from prospective
diabetes intervention studies in China, estimates of the in-
cidences and mortalities of the four diabetes complica-
tions (cardiovascular disease, retinopathy, nephropathy
and overt neuropathy) varied with the different strategies
used [35,36].
The different transition rates from the state of IGT to
onset of diabetes were used to reflect the natural history
of diabetes at different ages. For the study initiation age
of 40 years, the baseline transition rates for the preven-
tion groups were obtained from the cumulative inci-
dence of diabetes at the sixth year [12], and a 3-year
cumulative incidence of diabetes was used as the control
[32]. By using the ratio of diabetes incidence at ages 25, 40
and 60 years to adjust the baseline estimates at age
40 years, the transition rates from IGT to onset of diabetes
state for the initiation ages of 25 and 60 years were calcu-
lated. The ratio was approximately 1:2.6:8 according to
Dunstan et al. [33].
The life-table information was used to evaluate the
competing causes of death at the different initiation
ages [41].Economic variables
The costs of all expenditure relating to diabetes preven-
tion and treatment were collected from a societal per-
spective, including direct medical, direct nonmedical
and indirect costs [42]. Generally, the direct medical
costs were co-payment fees for treatment, diagnostic
testing, prescription drugs and medical supplies. Direct
nonmedical costs related to expenses for services like
transportation for the patient and family members to
clinics. The lost income of the patients and their families
as well as the costs for hiring nurses or care providers
were regarded as indirect costs [5].
Screening costs were the laboratory expenses that in-
cluded the cost of the initial 2-h PG screening test after
breakfast, and the confirmatory diagnostic OGTT in
subjects who had a positive PG test [37]. Costs assigned
to subjects in the IGT states included those from the
lifestyle interventions, such as the costs of increased
visits to the general practitioners and the counselling
sessions [38]. Costs for onset of diabetes state were sub-
mitted by the patients without complications, while aver-
age costs, which were applied to the diabetes complication
states, were calculated by dividing the total costs by the
number of patients with corresponding complications [5].
The costs in Chinese yuan were converted to US
dollars using the exchange rate as of June 15, 2007
(US$1 = CHY ―￥7.6948).
Quality-of-life variables
QALYs of subjects were calculated according to the time
spent with the health states and the utilities assigned to
these states [43]. For individuals with normal glucose
tolerance and IGT, the utilities were determined as 1
and 0.95, respectively [19]. The unadjusted median util-
ities for diabetes-related disorders were assigned to the
subjects at age 40 years [39,40], because these values
represented the median age and median social demog-
raphy of individuals having diabetes. The utilities of sub-
jects aged 25 and 60 years were calculated based on the
age-related characteristics of diabetes. In contrast to the
younger subjects with diabetes, the older subjects had
one more universal coexisting condition [44]. Thus,
using the coefficient of age and three coexisting condi-
tions (including diabetes and a given complication), the
utilities of the 60-year-old subjects with a complication
were determined by adjusting the baseline estimates of
subjects aged 40 years. For example, the utility of the
subjects with diabetes having CVD at the initiation age
of 60 years was 0.584, which was derived from the me-
dian utility of diabetes with CVD (0.674) and subtracting
0.006 [(60–40) × (−0.0003)] and 0.084 (the coefficient of
three conditions). For the individuals aged 25 years, the
calculation of utilities only considered the impact of age
















































Figure 1 Progression of individuals screened and intervened for diabetes. The hybrid tree combined a decision tree and Markov models.
The decision tree (the left side) consisted of five main arms representing five scenarios. The first three scenarios involved screening for
undiagnosed diabetes and IGT followed by any of the three active lifestyle interventions (diet, exercise, and duo-intervention), which were
applied to the IGT subjects. The fourth scenario involved screening for undiagnosed diabetes and IGT, but without formal interventions, and the
fifth scenario involved control group. Nine Markov models represented the nature history of diabetes (the lower right side). Each of them
consisted of eight states: IGT, normal glucose tolerance, onset of diabetes, four diabetes complication states and death. The IGT states were
tunnel states that included six temporary ones representing 6 years lifestyle interventions. Transition probability, costs, benefits were required for
each state. Three separate models were performed for strategies starting at age of 25, 40 and 60 respectively. “2-hour PG” means 2-hour plasma
glucose after breakfast. “DM” means diabetes mellitus. “OGTT” means oral glucose tolerance test. “IGT” means impaired glucose tolerance.
“NORMAL GT” represented normal glucose tolerance state. “DIABETES COMPLICATIONS” included four different diabetes complications states:
cardiovascular disease, retinopathy, nephropathy, and overt neuropathy disease. We numbered the transition paths corresponding to the main
transition parameters in Table 1. (#The complement probabilities of one branch. *The life-table information used to model competing causes of
death. @The proportion of individuals with normal PG. ¢, £, ¤ Transition parameters which determined whether a subject would receive
interventions. §, ¶, ß, ð, &: Transition parameters applied to the Markov models: ð1 to ð4 determined transitions from onset of diabetes state to
complications states respectively; &1 and &2 determined transitions from CVD or nephropathy to death state. We did not include the neuropathy-specific
and retinopathy-specific mortalities, since these complications are not fatal).
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with diabetes [45].
Costs and QALYs were discounted at the rate of 3%
[18]. Half-cycle corrections for both costs and health ef-
fects were applied to the model [28].
Sensitivity and statistical analysis
Sensitivity analyses were based on a change of one par-
ameter at a time. All parameters related to the perform-
ance of screening, prevalence of disease, costs, utilities
and discount rates were studied using sensitivity. Some
of the main assumptions were increased or decreased by
20%. These included positive rates of screening, incidence
of diabetes, incidence or mortality of diabetes-related dis-
orders, costs of screening, interventions and treatment of
diabetes-related disorders, and utilities associated with arange of health states. In particular, the assumptions
concerning the incidence of IGT were increased by 200%
and decreased by 50%, since the difference in prevalence
of IGT between young and old individuals is large in
China, almost 200% [3]. The sensitivity analyses of the de-
tection level of IGT from screening at 80% and 60% were
performed. For the compliance level of screening, 80%
and 60% were also performed. Changing the model inputs
allowed us to evaluate the robustness of the model.
The statistical analyses were performed with SAS 9.0
(SAS Institute Inc., Cary, NC, USA). The model simu-
lations were done with the software TreeAge 2011
Software (Williamstown, MA, USA). Continuous out-
comes were compared by use of the Wilcoxon rank-
sum test. Results with a p-value of <0.05 were considered
significant.
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Based on the hybrid decision tree Markov model, the
remaining survival years was 30.7 (19.8–41) for screened
subjects with diabetes and subjects with IGT who received
any of the three active lifestyle interventions (diet, exercise
or duo-intervention) using a start age of 25 years. For
screening alone, it was 30.2 (18.7–40.5) and 29.0 (18.5–
40.3) years for the control. The remaining life-years gained
that were induced by the prevention strategies ranged
from 1.2 to 1.7 years compared with the control. With re-
spect to the subjects with diabetes or IGT at the initiation
age of 40 years, the remaining survival years for screening
combined with the three lifestyle intervention strategies
was 20.1 (10.8–29.4) years, for screening alone it was 19.7
(10.4–29) years and for the control it was 19.6 (10.5–28.4)
years. The remaining survival life-years gained from inter-
ventions and from screening alone were approximately 0.5
and 0.1 years, respectively. When the initiation age went
up to 60 years, the remaining survival years went down to
7.5 (2.6–12.4) for the intervention strategy groups and 7.4
(2.5–12.4) for screening alone and for the control. In this
case, intervention strategies produced approximately a
0.1 year longer lifetime than with screening alone and with
the control. A significant difference of survival years was
found between the three lifestyle intervention strategies
and the other two groups at the initiation ages of 25 and
40 years, but not at 60 years.
Compared with the control, the IGT subjects who re-
ceived prevention strategies gained more years before
having diabetes or of any kind of diabetes-related com-
plication. We used the term extra time for these years.
Based on Table 3, all prevention strategies, except screen-
ing alone at the initiation age of 60 years, prolonged the
time before onset of diabetes, and also deferred the time
of onset of diabetes-related complications, i.e. extra time
was offered by preventions (4.48–5.20 years at age
25 years, 2.68–3.06 years at age 40 years, and less than
1 year at age 60 years). Additionally, the initiation ages
were found to show a proportional effect on extra time.
The results showed that both the screening with inter-
ventions and screening alone groups increased QALYs ofTable 3 The extra time gained for individuals with IGT before
different initiation ages
Different strategies
Years gained before deve
diabetes onset
Age 25 Age 40
Screening with diet intervention 2.51 1.59
Screening with exercise intervention 2.94 1.85
Screening with duo-intervention 2.88 1.81
Screening alone 0.04 0.01
Subjects with IGT who received prevention strategies gained more years before hav
time was used for these years. All prevention strategies, except screening alone at i
were found to show proportional effect on extra time.subjects either with diabetes or IGT compared with the
control (p <0.0001 within each age group) (Table 4).
Also, the increase in QALYs was considerably lower for
all prevention strategies at 60 years of age. Therefore,
the younger the age at screening, the more benefits were
achieved.
In relation to the economics, the average costs per
subject for the controls was $20,103, $13,634 and $8000
at the initiation ages of 25, 40 and 60 years, respectively,
which was much higher than that of the prevention
strategies within each initiation age. Therefore, screening
and lifestyle interventions were associated with greater
health benefits at a lower cost relative to no screening.
From a societal perspective, these prevention strategies
were economical at all initiation ages, especially in the
young cohort. However, the differences between inter-
ventions were not statistically significant (p >0.9999
within each age group).
The sensitivity analyses showed that the sensitivity of
cost savings and increment QALYs to 20% increases or de-
creases in the main assumptions, such as the screening
positive rate, incidence of diabetes and related complica-
tions, the total costs of screening, interventions and treat-
ment, all of the utilities associated with diabetes-related
disorders and the discount rates. Furthermore, sensitivity
of savings concerning the change of the transition rate of
IGT, which increased 200% and decreased 50%, was also
reported. The comparisons of the four prevention strat-
egies with the control were fairly insensitive for all of these
assumptions at the different initiation ages (see Additional
file 1). Conversely, by decreasing the detection level of IGT
and of the compliance level of screening, the costs per per-
son would increase and the savings would reduce for the
prevention strategies. As shown in Table 5, the savings in-
duced by the prevention strategies decreased 50% or more
at all initiation ages when the screening compliance rate
dropped to 60% (see Additional file 1 for more details).
Discussion
A literature search reveals that the only study of the cost ef-
fectiveness for diabetes interventions in an Asian developingdeveloping diabetes related disorders by preventions at
lopment of Years gained before development
of complications
Age 60 Age 25 Age 40 Age 60
0.49 4.48 2.68 0.68
0.57 5.20 3.06 0.78
0.55 5.11 3.00 0.75
0 0.08 0.02 0
ing diabetes and of any kind of complications than the control, the term extra
nitiation age of 60 years, offered some extra time. Moreover, the initiation ages
Table 4 The clinical and economic outcomes of prevention strategies and control (or compared with control) for






duo-intervention Screening alone Control
Initiation age of 25
Remaining life yearsI 30.7 30.7 30.7 30.2 29.0
Costs (US$)II
13294.77 13234.20 13241.38 18973.08 20102.87
(2750.37 - 27317.10) (2744.20 - 27306.59) (2745.42 - 27311.41) (3755.50 - 33613.01) (5334.50 - 37291.10)
Saving costs(US$)III 6808.10 6868.67 6861.49 1129.79 −
QALYsIV
17.98 17.98 17.98 17.05 14.65
(13.00 - 21.40) (13.10 - 23.40) (13.00 - 22.60) (13.20 - 23.00) (11.22 - 19.56)
Increment QALYsIII 3.33 3.33 3.33 2.40 −
Initiation age of 40
Remaining life yearsI 20.1 20.1 20.1 19.7 19.6
Costs (US$)II
9669.80 9659.97 9731.08 13180.33 13634.36
(2107.23 - 20052.17) (2106.35 - 20048.25) (2109.00 - 20055.12) (3161.46 - 26225.65) (4648.40 - 29925.24)
Saving costs(US$)III 3964.56 3974.39 3903.28 454.03 −
QALYs IV
15.47 15.46 15.47 14.25 12.88
(7.96 - 17.56) (7.76 - 17.56) (7.96 - 17.56) (6.84 - 15.64) (6.59 - 15.19)
Increment QALYsIII 2.59 2.58 2.59 1.37 −
Initiation age of 60
Remaining life yearsI 7.5 7.5 7.5 7.4 7.4
Costs (US$)II
5983.39 5921.23 5928.73 7606.03 8000.42
(1126.44 - 9436.12) (1119.18 - 9425.71) (1119.22 - 9429.12) (1939.74 - 10312.51) (2557.1 -16952.10)
Saving costs(US$)III 2017.03 2079.19 2071.69 394.39 −
QALYsIV
6.32 6.32 6.32 6.09 5.76
(4.26 - 11.33) (4.26 - 11.19) (4.30 - 11.23) (3.41 - 10.12) (3.35 - 9.65)
Increment QALYsIII 0.56 0.56 0.56 0.33 −
I: The figures were the mean values of remaining survival years per subject with IGT or diabetes. II: Costs (US$) were the average cost (95% credible intervals) per
subject, which arise for subjects from prevention and treatments of diabetes-related disorders during 40 years. III: Saving costs were the average cost per subject
in prevention groups in comparison with that of control; Increment QALYs were the average QALYs per subject diagnosed with IGT or diabetes in prevention
groups in comparison with that of control. IV: QALYs were the average QALYs per subject with IGT or diabetes (95% credible intervals).
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However, this study was only based on 3 years of short-term
follow-up and, therefore, does not reflect the long-term eco-
nomic profile of diabetes prevention. Our study has
conducted the first economic analysis of systematic preven-
tion for diabetes in China and includes a large amount ofTable 5 Sensitivity of saving costs (US$) per subject to differe
ages
Different strategies Reference Initiation age of 25
80% 60%
Screening with diet intervention 6808.10 5057.48 3084.12
Screening with exercise intervention 6868.67 5075.73 3091.46
Screening with duo-intervention 6861.49 5032.46 3066.46
Screening alone 1129.79 820.10 650.75
Data are saving costs (US$) per subject who received prevention strategies when th
The prevention strategies were still cost-saving at every initiation ages, though the
reduction of savings for all prevention strategies.high-quality data on benefits and costs, and also includes
various sensitivity analyses.
Significant differences of remaining survival years for
individuals with IGT or diabetes were found between
the three lifestyle intervention strategies (diet, exercise
and duo-intervention) and the other two groups (one-offnt compliance levels of screening initiated at different
Reference Initiation age of 40 Reference Initiation age of 60
80% 60% 80% 60%
3964.56 2885.25 1726.41 2017.03 1095.13 449.56
3974.36 2893.45 1716.15 2079.19 1069.45 498.66
3903.28 2811.16 1765.19 2071.69 1054.01 489.85
454.03 369.84 245.84 394.39 174.39 57.75
e compliance level of screening were dropped to 80% and 60% respectively.
declining level of compliance with screening had a great impact on that
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at the initiation ages of 25 and 40, but not 60 years.
Consistent with previous studies [12-14,16], our results
showed that the extra time for pre-diabetes before dia-
betes onset was existent, and it was 0.49–2.94 years at
the three initiation ages of the simulated intervention
strategies. This extra time was less than that found in
the USA where it was 6.3 years for prevention initiated
at age 30 years, 4.72–5.98 years at age 45 years, and
1.83 years at age 60 years or older [18]. A likely explan-
ation for this difference could be that diabetes was diag-
nosed much earlier and effective medications were
prescribed more widely in higher income countries,
while effective management and screening of diabetes
and IGT are fairly limited in developing countries
[3,46-48]. For the screening alone strategy, the extra
time was 0.04 years, which is comparable to the range of
0.02–0.08 reported in the UK and Taiwan [19,20,26].
Consequently, the strategy of screening alone, which re-
sults in early monitoring or treatment for diabetes, can
improve health [49]. In terms of preventing complica-
tions, there is now a broad consensus that the earlier
diabetes is detected and treated, the greater the likeli-
hood that complications will be prevented or delayed
[27]. Our study has further confirmed that screening
and interventions increase the time before developing
any complications in IGT subjects.
The estimated costs of screening and lifestyle interven-
tions in this study ($360–$370 per year) are much lower
than those of the Diabetes Prevention Programme
conducted in the USA ($2780 per year) [11]. This lower
cost is primarily because of the following reasons: (i) the
personnel costs in developing countries are lower, (ii)
our study was based on simulated community interven-
tions, which included group counselling instead of the
more costly one-to-one clinical trials, and (iii) the aver-
age cost of diabetes intervention in a typical Chinese
community was estimated from a later starting period
than that of the American programme that started dur-
ing the initial phase of intervention, which is a more
costly period since it included frequent laboratory tests
and clinical follow-ups. Although the prevention costs
are lower in developing countries, some patients may
still be unwilling to pay the costs especially for long-
term preventions, such as in China. This is mainly owing
to the fact that most Chinese have to pay all prevention
expenses out of their own pockets irrespective of the in-
surance plan that they have [50]. This situation differs
from that in many European countries where insurance
companies and other health providers cover most costs
of the prevention programmes [51].
In the present study, all simulated screening strategies
reduced the lifetime costs by approximately $390 or
more per screened subject at all the initiation ages ascompared with the control; in other words, all the pre-
vention programmes were cost saving. These results are
not only considered economically attractive by inter-
national standards [21], but are also seen as better than
some cost-effective diabetes prevention programmes in
high-income countries, such as in Taiwan ($17,113 per
QALY gained) [19], Australia ($10,142 per QALY gained)
[52], USA ($9731 per QALY gained) [18] and UK ($8358
per QALY gained) [26]. It is noteworthy that the least
savings gained by interventions in our study were ap-
proximately $2000 per subject among different initiation
ages, which is still more than that of some cost-saving
countries like Mexico ($1000 saved per subject) [53],
Switzerland ($1040 saved per subject) and Germany
($600 saved per subject) [54]. This benefit is due to the
long-term effects beyond the intervention period for
postponing or averting diabetes and related complications,
which bring about substantial high medical costs in China
[4,5], even when the interventions were performed for just
6 years.
Among the three simulated intervention programmes,
screening with exercise had the greatest savings at all
three starting ages compared with the control. How-
ever, the differences between these three lifestyle in-
terventions were insignificant. A possible explanation
for this could be that the incidences and mortalities
of the main diabetes-related complications that we
used were the same, since these parameters were cal-
culated after combining the different lifestyle inter-
vention groups [35,36].
Targeting a population at an appropriate age for re-
ceiving preventive intervention should be more effective
for lowering costs than by targeting a non-specific age.
Because the best net health benefits and the greatest sav-
ing costs were realized at the age of 25 years, selection
of appropriate age groups should not ignore the young
adults in developing countries, even though the current
recommendations in developed countries are that screen-
ing should begin at the age of 45 years [21]. As for older
subjects, lifestyle intervention was also observed to result
in a reduction of costs and more favourable health conse-
quences, which is similar to the pharmacological interven-
tions [55]. However, these results were not as marked as
those for the young and middle-aged, as the older patients
with pre-diabetes were not as susceptible to improve-
ments because they responded poorly to a single lifestyle
intervention as compared with receiving two or more in-
terventions together [56]. Furthermore, along with the
higher incidence and mortality of disease and the signifi-
cant complications or comorbidities [41,51], the older
subjects with IGT were more likely to remain in the death
or diabetes-related disorder states since there was no
intervention at all in the screening alone and control
groups.
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were not sensitive to the changes of reference assump-
tions and they still supported the conclusion, i.e. screen-
ing and intervention strategies are cost saving. Because
of the chronic and asymptomatic nature of diabetes,
screening performance and compliance are important is-
sues for diabetes prevention. Similar to previous studies
[26], we found that a lower detection level of IGT from
screening and lower compliance with screening resulted
in higher costs and lower health effectiveness. However,
the prevention programmes may still be worth expanding
in China, since they were shown to be cost saving. Mean-
while, maintaining high rates of screening performance
and compliance will lead to favourable clinical and eco-
nomic effects on diabetes prevention.
There were also a few limitations of this study. First, the
utilities we used were estimated based on the US popula-
tion, and they may be on the low side compared with
Chinese circumstances [57,58]. Thus, the overall QALYs
would increase when the China-specific utilities are avail-
able. Nonetheless, the lower utilities might not have signifi-
cant impact on the stability of the models, since the saving
costs were not very sensitive to most changes of utilities.
A second limitation of this study was that the longer life
span induced by preventions may result in additional ex-
penditures called ‘future costs’, which probably should
have been considered in the economic analysis [59]. Un-
fortunately, because of the lack of comprehensive data to
estimate the future costs accurately [60], we only included
the costs of diabetes prevention and treatments during the
simulated 40 years. However, it has been shown that eco-
nomic analysis, excluding future costs and effects, could
still maintain internal consistency [60].
A third limitation was that the influence of repeated
screening was not assessed in this study. The saving
costs for longer time interval screening ought to be simi-
lar to that of one-off screening, while it might decrease
for short interval screening, because the prevalence of
undiagnosed diabetes and IGT could possibly be lower
and result in a higher cost per case [18,20]. The sensitiv-
ity analyses suggested that the saving costs of all strat-
egies were insensitive to the prevalence of IGT and
diabetes, that is, whether a subject undergoes a repeat
screening might not actually affect our results.
Finally, this study did not consider the impact of be-
havioural or biomarker risk factors such as smoking and
haemoglobin A1c concentration [24,51]. Also, the poten-
tial benefits of screening and management of related dis-
orders like hypertension and hyperlipidaemia were not
taken into account [3,18]. Further investigations of
China-specific clinical data with reference to the related
subgroups should be explored.
Despite these limitations, the model truly reproduces
the effects of diabetes screening and lifestyle interventions.Comprehensive validations that were performed further
promoted the accuracy of the model. The findings of this
study should be applicable to real lives in China and other
developing countries, and it should be able to assist gov-
ernments of developing countries on strategic decision
making regarding health resource allocation over the long
term.Conclusions
Compared with high-income areas, developing countries
are deficient in the effective management of diabetes
screening in the general population and in early diagno-
sis to enable timely IGT interventions, because of insuf-
ficient resources and practical considerations. Policies of
one-off screening for undiagnosed diabetes and IGT,
followed by appropriate lifestyle interventions for those
with IGT, are cost saving. These policies represent the
effective use of healthcare resources in developing coun-
tries, especially when they are applied to young adults.Additional file
Additional file 1: Sensitivity of saving costs (US$) or increment
QALYs to different assumptions for prevention strategies or control.
This file involved the results of sensitivity analyses to different
assumptions for different strategies, figures in tables were saving costs
(US$) or increment QALYs. The file consisted of four separate sheets.
Sheet 1 named “Performance and Compliance” involving the sensitivity
of saving costs (US$) and increment QALYs to different compliance and
detection level of screening at different initiation ages. The sheet 2–4
named “Initiation age of 25”, “Initiation age of 40” and “Initiation age of
60” respectively, involving the sensitivity of saving costs (US$) or
increment QALYs to different assumptions for preventions strategies
starting at age of 25, 40 and 60 years. In each sheet, the “OGTT” means
oral glucose tolerance test. “IGT” means impaired glucose tolerance.
“QALYs” means quality-adjusted life-years. As shown in sheet 1,
decreasing the detection level of IGT and of the compliance level of
screening would increase the costs per subject, and would result in a
reduction of health effectiveness of subjects with diabetes or IGT in
prevention groups. Sheet 2–4 showed the sensitivity of saving costs (US
$) or increment QALYs to 20% increase or decrease in most assumptions,
except the incidence of IGT which increased 200% and decreased 50% at
all initiation ages. The insensitive results still supported the main
conclusion that screening and intervention strategies for diabetes were
cost-saving in China.Abbreviations
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